Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,906,964
  • Shares Outstanding, K 73,373
  • Annual Sales, $ 772,600 K
  • Annual Income, $ 131,100 K
  • 60-Month Beta 0.79
  • Price/Sales 2.47
  • Price/Cash Flow 13.10
  • Price/Book 1.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.40
  • Number of Estimates 2
  • High Estimate 0.40
  • Low Estimate 0.40
  • Prior Year 0.38
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.08 +4.03%
on 05/29/19
26.94 -10.88%
on 05/16/19
-2.57 (-9.67%)
since 05/14/19
3-Month
23.08 +4.03%
on 05/29/19
35.24 -31.87%
on 05/07/19
-10.13 (-29.67%)
since 03/14/19
52-Week
23.08 +4.03%
on 05/29/19
50.44 -52.40%
on 09/04/18
-14.82 (-38.17%)
since 06/14/18

Most Recent Stories

More News
Best Relative Performance in the Biotechnology Industry Detected in Shares of Myriad Genetics (MYGN , ACOR , KPTI , INSM , CYTK )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

MYGN : 24.01 (-7.62%)
KPTI : 5.71 (-0.70%)
ACOR : 7.53 (-0.92%)
Myriad Genetics Rises 3.52% on Heavy Volume: Watch For Potential Pullback

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $24.55 to a high of $25.34. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of...

MYGN : 24.01 (-7.62%)
Myriad Genetics Set to Possibly Pullback After Yesterday's Rally of 3.52%

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $24.55 to a high of $25.34. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of...

MYGN : 24.01 (-7.62%)
Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MYGN : 24.01 (-7.62%)
AngioDynamics Divests NAMIC Portfolio to Medline Industries

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

VAR : 130.88 (-0.91%)
ARAY : 3.71 (-0.27%)
MYGN : 24.01 (-7.62%)
ANGO : 19.50 (-0.41%)
Myriad Genetics Announces Study Results Of myRisk Cancer Test

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

TECH : 208.34 (-1.37%)
MYGN : 24.01 (-7.62%)
AYTU : 1.74 (-1.42%)
ACOR : 7.53 (-0.92%)
Outset Medical Appoints New Chief Financial Officer

Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced the appointment of Rebecca Chambers as Chief Financial...

MYGN : 24.01 (-7.62%)
Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global...

MYGN : 24.01 (-7.62%)
Myriad Genetics' (MYGN) POLO Study Shows Positive Results

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

CERN : 72.23 (-0.34%)
MYGN : 24.01 (-7.62%)
BRKR : 45.55 (-0.48%)
PEN : 166.83 (+1.96%)
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk(R) Hereditary Cancer Test at American Society of Clinical Oncology

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk Hereditary Cancer test will be featured today...

MYGN : 24.01 (-7.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 27.31
1st Resistance Point 25.66
Last Price 24.01
1st Support Level 22.94
2nd Support Level 21.87

See More

52-Week High 50.44
Fibonacci 61.8% 39.99
Fibonacci 50% 36.76
Fibonacci 38.2% 33.53
Last Price 24.01
52-Week Low 23.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar